Skip to main
  1. Stocks
  2. Actuate Therapeutics Inc
  3. Forecast
ACTU

ACTU Stock Forecast & Price Target

ACTU Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actuate Therapeutics is viewed favorably because oral elraglusib could materially improve exposure versus the IV formulation, with PK modeling suggesting 1–2 tablets daily may reach targeted levels and preclinical bioavailability above 95%. FDA clearance for the Phase 1/2 study, following the April 2026 IND filing, supports a potential 2H26 start and a relatively short path to pivotal development by 2H27 if safety and efficacy hold. The pediatric neuroblastoma program adds optionality, with 53% clinical response or disease control in 10 of 19 heavily pretreated patients, and a possible rare pediatric disease PRV worth approximately $150M to $200M, though additional funding may be needed.

Bears say

Actuate Therapeutics is a clinical-stage biopharmaceutical company with no revenues in 1Q26 or 2Q26, underscoring a dependence on future clinical success rather than current commercial cash flow. Its losses remain persistent at $0.24 per diluted share in 1Q26 and $0.20 in 2Q26, while projected 2026 net losses of $0.84 and $0.61 per diluted share highlight continuing operating burn. Liquidity is also strained, with cash and cash equivalents falling from $8.1M at the end of 1Q26 to $4.44M at the end of 2Q26, and management indicating funds are not sufficient to support operations beyond September 2026.

ACTU has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

ACTU Analyst Forecast & Price Prediction

Get the latest ACTU stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ACTU

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actuate Therapeutics Inc (ACTU) Forecast

Analysts have given ACTU a Strong Buy based on their latest research and market trends.

According to 2 analysts, ACTU has a Strong Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actuate Therapeutics Inc (ACTU)


ACTU Analyst Forecast & Price Prediction

Get the latest ACTU stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ACTU

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ACTU stock data and trends